Folgen
Anneke Susanne de Vos
Anneke Susanne de Vos
Zugehörigkeit unbekannt
Bestätigte E-Mail-Adresse bei umcutrecht.nl
Titel
Zitiert von
Zitiert von
Jahr
Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in A msterdam; evidence for harm reduction?
AS de Vos, JJ van der Helm, A Matser, M Prins, MEE Kretzschmar
Addiction 108 (6), 1070-1081, 2013
912013
Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first?
AS de Vos, M Prins, MEE Kretzschmar
Addiction 110 (6), 975-983, 2015
552015
Cost-effectiveness of hepatitis C treatment for people who inject drugs and the impact of the type of epidemic; extrapolating from Amsterdam, the Netherlands
DK van Santen, AS de Vos, A Matser, SB Willemse, K Lindenburg, ...
PloS one 11 (10), e0163488, 2016
532016
Reassessing the human immunodeficiency virus type 1 life cycle through age-structured modeling: life span of infected cells, viral generation time, and basic reproductive …
CL Althaus, AS De Vos, RJ De Boer
Journal of virology 83 (15), 7659-7667, 2009
532009
Cost‐effectiveness of the screening of blood donations for hepatitis E virus in the Netherlands
AS de Vos, MP Janssen, HL Zaaijer, BM Hogema
Transfusion 57 (2), 258-266, 2017
492017
Determinants of persistent spread of HIV in HCV-infected populations of injecting drug users
AS de Vos, JJ van der Helm, M Prins, ME Kretzschmar
Epidemics 4 (2), 57-67, 2012
312012
Are alternative strategies required to accelerate the global elimination of lymphatic filariasis? Insights from mathematical models
WA Stolk, JM Prada, ME Smith, P Kontoroupis, AS De Vos, P Touloupou, ...
Clinical infectious diseases 66 (Supplement_4), S260-S266, 2018
272018
Benefits of hepatitis C virus treatment: A balance of preventing onward transmission and re-infection
AS De Vos, MEE Kretzschmar
Mathematical biosciences 258, 11-18, 2014
262014
Impact of hepatitis E virus testing on the safety of blood components in Germany–results of a simulation study
C Kamp, J Blümel, SA Baylis, I Bekeredjian‐Ding, M Chudy, M Heiden, ...
Vox Sanguinis 113 (8), 811-813, 2018
242018
The effect of assortative mixing on stability of low helminth transmission levels and on the impact of mass drug administration: Model explorations for onchocerciasis
AS de Vos, WA Stolk, SJ de Vlas, LE Coffeng
PLoS Neglected Tropical Diseases 12 (10), e0006624, 2018
192018
The efficiency of targeted intervention in limiting the spread of HIV and Hepatitis C Virus among injecting drug users
AS De Vos, MEE Kretzschmar
Journal of theoretical biology 333, 126-134, 2013
192013
Temporal trends in mortality among people who use drugs compared with the general Dutch population differ by hepatitis C virus and HIV infection status
DK Van Santen, JJ van der Helm, BPX Grady, AS de Vos, ...
Aids 28 (17), 2589-2599, 2014
172014
Assessing the dynamic changes in vitiligo: reliability and validity of the Vitiligo Disease Activity Score (VDAS) and Vitiligo Disease Improvement Score (VDIS)
N van Geel, L Depaepe, V Vandaele, L Mertens, J Van Causenbroeck, ...
Journal of the European Academy of Dermatology and Venereology 36 (8), 1334-1341, 2022
152022
Treatment as prevention among injecting drug users; extrapolating from the Amsterdam cohort study
AS de Vos, M Prins, RA Coutinho, JJ van der Helm, MEE Kretzschmar
AIDS 28 (6), 911-918, 2014
112014
Bioenergetics, overcompensation, and the source–sink status of marine reserves
D Claessen, AS de Vos, AM de Roos
Canadian Journal of Fisheries and Aquatic Sciences 66 (7), 1059-1071, 2009
112009
A novel approach to detect test‐seeking behaviour in the blood donor population: making the invisible visible
AS De Vos, RW Lieshout‐Krikke, E Slot, EA Cator, MP Janssen
Vox Sanguinis 111 (3), 274-280, 2016
92016
The impact of mass drug administration expansion to low onchocerciasis prevalence settings in case of connected villages
AS de Vos, WA Stolk, LE Coffeng, SJ de Vlas
PLoS Neglected Tropical Diseases 15 (5), e0009011, 2021
62021
Understanding MRSA clonal competition within a UK hospital; the possible importance of density dependence
AS de Vos, SJ De Vlas, JA Lindsay, MEE Kretzschmar, GM Knight
Epidemics 37, 100511, 2021
52021
Markers of epidemiological success of methicillin-resistant Staphylococcus aureus isolates in European populations
VO Baede, A Gupta, GM Knight, LM Schouls, K Laing, M Tavakol, ...
Clinical Microbiology and Infection 29 (9), 1166-1173, 2023
42023
Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam: evidence for harm reduction?
AS De Vos, JJ Van Der Helm, M Prins, MEE Kretzschmar
Journal of the International AIDS Society 15, 78-78, 2012
42012
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20